Emcure Pharmaceuticals Intrinsic Value
Emcure Pharmaceuticals intrinsic value. Emcure Pharmaceuticals (EMCURE) median intrinsic value is ₹793.51 from 10 valuation models (range ₹524–₹1130), vs current price ₹1937.10 — -59.0% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit Emcure Pharmaceuticals share price chart.
EMCURE Valuation Methods Summary — DCF, Graham Number & P/E
Emcure Pharmaceuticals intrinsic value across 10 models vs current price ₹1937.10 — upside/downside and value range per method. Compare with EMCURE fundamental valuation to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1129.92 | ₹903.94 - ₹1355.90 | -41.7% | EPS: ₹51.36, Sector P/E: 22x |
| Book Value Method | asset | ₹523.89 | ₹471.50 - ₹576.28 | -73.0% | Book Value/Share: ₹261.95, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1045.89 | ₹941.30 - ₹1150.48 | -46.0% | Revenue/Share: ₹522.95, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1040.00 | ₹936.00 - ₹1144.00 | -46.3% | EBITDA: ₹1976.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹774.84 | ₹619.87 - ₹929.81 | -60.0% | CF Growth: 5.3%, Discount: 15% |
| PEG Ratio Method | growth | ₹581.13 | ₹523.02 - ₹639.24 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹793.51 | ₹714.16 - ₹872.86 | -59.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹968.55 | ₹871.69 - ₹1065.40 | -50.0% | ROE: 19.6%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹581.13 | ₹523.02 - ₹639.24 | -70.0% | EPS: ₹51.36, BVPS: ₹261.95 |
| Dividend Yield Method | dividend | ₹581.13 | ₹523.02 - ₹639.24 | -70.0% | DPS: ₹3.60, Target Yield: 2.5% |
EMCURE Intrinsic Value vs Market Price — All Valuation Models
Emcure Pharmaceuticals fair value range ₹524–₹1130 vs current market price ₹1937.10 across 10 valuation models. Read Emcure Pharmaceuticals dividend policy for the complete payout history and dividend yield track record.
EMCURE Intrinsic Value Analysis — Undervalued or Overvalued?
Emcure Pharmaceuticals median intrinsic value ₹793.51, current price ₹1937.10 — Trading Above Calculated Value by 59.0%, margin of safety -100.0%.
What is the intrinsic value of EMCURE?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Emcure Pharmaceuticals (EMCURE) is ₹793.51 (median value). With the current market price of ₹1937.10, this represents a -59.0% variance from our estimated fair value.
The valuation range spans from ₹523.89 to ₹1129.92, indicating ₹523.89 - ₹1129.92.
Is EMCURE undervalued or overvalued?
Based on our multi-method analysis, Emcure Pharmaceuticals (EMCURE) appears to be trading above calculated value by approximately 59.0%.
EMCURE Financial Health — Key Ratios vs Industry Benchmarks
Emcure Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 7.75 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 19.6% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.03x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
EMCURE Cash Flow Quality — Operating & Free Cash Flow
Emcure Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹944 Cr | ₹357 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹852 Cr | ₹804 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1,097 Cr | ₹740 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹747 Cr | ₹513 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹768 Cr | ₹481 Cr | Positive Free Cash Flow | 8/10 |